B
Bull
Bull · 25%BWAY
$14.03
Scenario price
$11.250
-0.187 (-1.66%)At close
Loading chart…
- High
- 11.400
- Open
- 11.400
- VWAP
- 11.25
- Volume
- 52.46K
- Mkt Cap
- 100.32M
- Low
- 11.090
- Amount
- 590.00K
- EV/EBITDA, TTM
- 29.80
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
AI analysis of Brainsway Ltd (BWAY)
HoldWhile Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
Valuation Metrics
The current forward P/E ratio for Brainsway Ltd (BWAY) is 17.92, compared to its 5-year average forward P/E of 42.63.
Alphio AI Price Scenarios for BWAY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BWAY
Events Timeline
News
7.510-19NewsfilterBrainsWay Partners with IPMG to Enhance Mental Health Treatments
- 8.510-13Newsfilter
BrainsWay Expands Medical Policy Coverage for SWIFT TMS Protocol
- 9.009-08Newsfilter
BrainsWay Announces Pilot Study Results on Depression Treatment
- 9.008-27Newsfilter
BrainsWay Publishes New Data on Depression Treatment
- 9.508-12Newsfilter
BrainsWay Reports 35% Revenue Growth in Q2 2026
BWAY FAQ — answered by Alphio AI
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.